Anteris Technologies Global (NASDAQ:AVR) Major Shareholder Purchases 74,286 Shares of Company Stock

Posted by John Perry on Oct 2nd, 2026

Anteris Technologies Global Corp. (NASDAQ:AVR – Get Free Report) major shareholder L1 Capital Pty Ltd bought 74,286 shares of Anteris Technologies Global stock in a transaction dated Wednesday, September 30th. The stock was acquired at an average price of $7.72 per share, with a total value of $573,487.92. Following the purchase, the insider directly owned 4,877,827 shares of the company’s stock, valued at approximately $37,656,824.44. This represents a 1.55% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

L1 Capital Pty Ltd also recently made the following trade(s):

On Thursday, October 1st, L1 Capital Pty Ltd purchased 322,940 shares of Anteris Technologies Global stock. The shares were acquired at an average price of $7.60 per share, for a total transaction of $2,454,344.00.
On Friday, August 28th, L1 Capital Pty Ltd sold 7,800 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.83, for a total transaction of $68,874.00.
On Tuesday, August 11th, L1 Capital Pty Ltd sold 375,815 shares of Anteris Technologies Global stock. The shares were sold at an average price of $9.30, for a total transaction of $3,495,079.50.
On Monday, August 10th, L1 Capital Pty Ltd sold 251,844 shares of Anteris Technologies Global stock. The stock was sold at an average price of $9.10, for a total value of $2,291,780.40.
On Thursday, August 6th, L1 Capital Pty Ltd sold 174,721 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.10, for a total value of $1,415,240.10.
On Tuesday, August 4th, L1 Capital Pty Ltd sold 480,608 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.30, for a total value of $3,989,046.40.
On Wednesday, August 5th, L1 Capital Pty Ltd sold 14,581 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.23, for a total value of $120,001.63.
On Monday, August 3rd, L1 Capital Pty Ltd sold 475,693 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.10, for a total transaction of $3,853,113.30.
On Friday, July 31st, L1 Capital Pty Ltd sold 48,711 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.15, for a total transaction of $396,994.65.
On Wednesday, July 29th, L1 Capital Pty Ltd sold 155,505 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.04, for a total value of $1,250,260.20.

Anteris Technologies Global Price Performance

NASDAQ AVR traded down $0.16 during trading on Thursday, reaching $7.61. The company’s stock had a trading volume of 1,170,680 shares, compared to its average volume of 718,688. The firm has a fifty day moving average of $8.51 and a 200 day moving average of $7.98. Anteris Technologies Global Corp. has a one year low of $3.30 and a one year high of $11.06. The stock has a market capitalization of $741.67 million, a PE ratio of -3.90 and a beta of 1.87.

Anteris Technologies Global (NASDAQ:AVR – Get Free Report) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. The business had revenue of $1.01 million for the quarter, compared to the consensus estimate of $1.50 million. During the same quarter last year, the business posted ($0.58) EPS. Research analysts expect that Anteris Technologies Global Corp. will post -1.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Anteris Technologies Global

A number of institutional investors have recently made changes to their positions in AVR. BlackRock Inc. bought a new position in shares of Anteris Technologies Global during the 2nd quarter valued at $56,846,000. ADAR1 Capital Management LLC boosted its position in Anteris Technologies Global by 205.9% during the first quarter. ADAR1 Capital Management LLC now owns 3,789,132 shares of the company’s stock valued at $21,030,000 after buying an additional 2,550,355 shares during the period. Perceptive Advisors LLC grew its stake in shares of Anteris Technologies Global by 104.4% during the first quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock valued at $19,011,000 after buying an additional 1,750,000 shares during the last quarter. Nantahala Capital Management LLC bought a new position in shares of Anteris Technologies Global during the second quarter valued at about $33,325,850. Finally, Affinity Asset Advisors LLC increased its holdings in shares of Anteris Technologies Global by 87.5% in the first quarter. Affinity Asset Advisors LLC now owns 912,397 shares of the company’s stock worth $5,064,000 after buying an additional 425,713 shares during the period.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on AVR. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 price objective on shares of Anteris Technologies Global in a report on Friday, August 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Anteris Technologies Global in a research report on Wednesday, August 26th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

View Our Latest Stock Report on AVR

About Anteris Technologies Global

(Get Free Report)

Anteris Technologies Global Corp. is a medical device company focused on developing advanced technologies for structural heart disease. Its primary product candidate is the DurAVR transcatheter heart valve, designed to treat aortic valve stenosis through a minimally invasive transcatheter aortic valve replacement procedure.

The DurAVR valve is based on Anteris’ ADAPT tissue-engineering technology and is manufactured as a single-piece valve intended to replicate the performance and natural hemodynamics of a healthy human aortic valve.